Toremifene (citrate)

Toremifene (citrate)

• CAS Number: 89778-27-8
• UNSPSC Description: Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 μM and 2.6 μM, respectively[1][2].
• Target Antigen: Apoptosis; Estrogen Receptor/ERR
• Type: Reference compound
• Related Pathways: Apoptosis;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/toremifene-citrate.html
• Purity: 99.75
• Solubility: DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL
• Smiles: ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O
• Molecular Weight: 598.08
• References & Citations: [1]Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7(Suppl 3): S30-S35.|[2]Gauri J Sabnis, Luciana Macedo, Olga Goloubeva, Toremifene - Atamestane; Alone or In Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol. 2008 January; 108(1-2): 1-7.|[3]Taneja SS, Morton R, Barnette G, Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013 Feb 10;31(5):523-9.|[4]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.Cell Rep Methods. 2023 Oct 23;3(10):100599.|J Med Chem. 2020 Oct 8;63(19):11085-11099.|Viruses. 2021 Jun 28;13(7):1255.|bioRxiv. 2020 May.|J Pharmaceut Biomed. 2020, 113870.|Patent. US11696914.|Research Square Preprint. 2020 Nov 4;rs.3.rs-100914.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched